DaVinci Biosciences LLC, of Costa Mesa, CA, announced today the presentation of their safety and feasibility study demonstrating the administration of autologous bone marrow derived stem cells for the treatment of acute and chronic spinal cord injury at Neuroscience 2009, Society for Neuroscience’s 39th Annual Meeting, to be held at McCormick Convention Center in Chicago, IL. Rafael Gonzalez, Ph.D., Director of Research and Development for DaVinci Biosciences LLC will present the work during the conference on October 20, 2009 and be available to answer questions regarding the study, following his presentation.
“We are excited to share the findings
A biopolymer could aid in the regrowing of nerves induced by the use of stem cells according to a new research project that gives hope to people who have been in an accident and have lost the use of one or more limbs. The procedure will enter into clinical testing in January after animal testing has been completed.
The Experimental Neurological Institute (INSPE), founded in 2005 at San Raffaele Hospital of Milan became operational with the inauguration of more than 1,200 square meters of lab space entirely dedicated to general and clinical research therapies for serious neurological diseases,
An injectable hydrogel could aid recovery from brain injury by helping stimulate tissue growth at the site of the wound, researchers say.
Research on rats suggests the gel, made from synthetic and natural sources, may spur growth of stem cells in the brain (…)
Researchers say the advantage of the new gel, which is injected into the injury in liquid form, is that it can be loaded with different chemicals to stimulate various biological processes.
Neuralstem Inc. has received the green light to begin the first human stem cell trial to treat Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig’s disease. The company’s stock soared on the news.
Neuralstem has only received approval for the first stage of the trial that would consist of 12 patients who will receive stem cell injections in the lumbar area of the spinal cord.
Neuralstem said the trial will be under the direction of principal investigator Dr. Eva L. Feldman, Director of the University of Michigan Health System ALS Clinic and the Program for Neurology Research & Discovery.
An estimated 400.000 Americans suffer from multiple sclerosis, but the findings of a new clinical trial shows promise in the fight to reverse symptoms of MS.
Researchers at Northwestern University conducted a trial using patients’ own stem cells to treat symptoms of multiple sclerosis, reports Early Show correspondent Debbye Turner Bell, and although the study group was small — only 21 patients participated in it — the findings are a huge breakthrough in the fight against MS.
Edwin McClure is strong and healthy now, but just four years ago, his life was very different.
“I would get fatigued. I couldn’t deal with